U.S. Health Economic Analysis Demonstrates the Cost Reduction Impact of Using B R A H M S PCT to Support Antibiotic Stewardship Versus Standard of Care
WALTHAM, Mass., May 23, 2019 /PRNewswire/ -- A new health economic analysis published in the journal PLOS One, compared the cost impact of using B R A H M S PCT (Procalcitonin) assays to support antibiotic stewardship decisions versus the standard of care for patients with suspected sepsis or lower respiratory tract infections (LRTI) in the United States. Procalcitonin is a biomarker that aids clinical decision-making about when to initiate and discontinue antibiotic therapy for inpatients or patients in the emergency department with suspected or confirmed LRTI. The biomarker also aids in decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis. Several cost analyses have been conducted on Procalcitonin aiding in antibiotic stewardship, but none using data primarily from the United States.
More than 1.7 million people in the U.S. are diagnosed with sepsis each year(1,2,3) and it is the number one cost of hospitalization in the U.S. consuming more than $27 billion each year(4,5,6,7). LRTIs are among the most common reasons for antibiotic prescription(8) and an estimated 30 to 85 percent of these prescriptions are unnecessary or inappropriate(9-17). Even when indicated, antibiotic treatment courses often exceed recommended durations(17).
A previously published health economic decision model was used to compare the costs and effects of B R A H M S PCT assay in supporting antibiotic stewardship decisions. The analysis considered the societal and hospital perspective with a time horizon covering the length of hospital stay. The main endpoints were total costs per patient, including treatment costs and productivity losses, the number of patients with antibiotic resistance or C.difficile infections, and costs per antibiotic day avoided.
"My clinical experience is consistent with the scientific data, demonstrating how the monitoring of bacterial infections with B R A H M S PCT assay can reduce the costs associated with the management of LRTI and sepsis patients through reductions in length of stay and antibiotic usage," said H. Bryant Nguyen, MD, John E. Peterson Professor of Medicine and Chief of Pulmonary & Critical Care Medicine at Loma Linda University, Loma Linda, California.
Based on the results, the authors concluded that using B R A H M S PCT assay to aid in decisions about antibiotic use for hospitalized patients with suspected sepsis and LRTI is associated with a reduction in antibiotic days, a shorter length of stay on the regular ward and the intensive care unit, shorter duration of mechanical ventilation, and fewer patients at risk for antibiotic resistance or C.difficile infection. Total costs in the B R A H M S PCT assay group compared to standard care were reduced by 26.0percent in sepsis and 17.7percent in lower respiratory tract infection (total incremental costs of -$11,311 per patient and -$2,867 per patient respectively).
Availability of product in each country depends on local regulatory marketing authorization status.
About B?R?A?H?M?S PCT
B?R?A?H?M?S PCT assay provides information on the presence and severity of bacterial infection, helping physicians in emergency departments, intensive care and other hospital units decide whether to initiate antibiotic therapy in patients with suspected or confirmed lower respiratory tract infections (LRTI) and when to safely discontinue antibiotics in patients with LRTI and sepsis. In clinical studies, B R A H M S PCT assay has been shown to reduce the antibiotic prescription rate and duration in patients with LRTI, defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Evaluating the decline in B R A H M S PCT assay levels over time aids clinicians in determining whether to discontinue antibiotic therapy for patients with LRTI or sepsis, without compromising patient safety.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Reference
1. http://jamanetwork.com/journals/jama/fullarticle/2654187
2. http://www.nejm.org/doi/full/10.1056/NEJMoa022139
3. https://www.cdc.gov/nchs/data/databriefs/db62.pdf
4. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hosp
ital-Conditions.pdf
5. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb225-Inpatient-US-Stays-
Trends.jsp
6. https://www.bloomberg.com/news/articles/2017-07-14/america-has-a-27-billi
on-sepsis-crisis
7. http://www.journalofinfection.com/article/S0163-4453(16)30288-2/fulltext
8. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for
acute respiratory tract infections in US ambulatory settings. JAMA 2009;
302:758.
9. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of
Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits,
2010-2011. JAMA 2016; 315:1864.
10. Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for
adults in ambulatory care in the USA, 2007-09. J Antimicrob Chemother
2014; 69:234.
11. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic
use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014; 63:194.
12. McKay R, Mah A, Law MR, et al. Systematic Review of Factors Associated
with Antibiotic Prescribing for Respiratory Tract Infections. Antimicrob
Agents Chemother 2016; 60:4106.
13. Kraus EM, Pelzl S, Szecsenyi J, Laux G. Antibiotic prescribing for acute
lower respiratory tract infections (LRTI) - guideline adherence in the
German primary care setting: An analysis of routine data. PLoS One 2017;
12:e0174584.
14. Silverman M, Povitz M, Sontrop JM, et al. Antibiotic Prescribing for
Nonbacterial Acute Upper Respiratory Infections in Elderly Persons. Ann
Intern Med 2017; 166:765.
15. McCullough AR, Pollack AJ, Plejdrup Hansen M, et al. Antibiotics for
acute respiratory infections in general practice: comparison of
prescribing rates with guideline recommendations. Med J Aust 2017;
207:65.
16. Ebell MH, Radke T. Antibiotic use for viral acute respiratory tract
infections remains common. Am J Manag Care 2015; 21:e567.
17. Hecker MT, Aron DC, Patel NP, et al. Unnecessary use of antimicrobials
in hospitalized patients: current patterns of misuse with an emphasis on
the antianaerobic spectrum of activity. Arch Intern Med 2003; 163:972.
Media Contact Information:
Secondary Contact Information:
Amy Crosby
Dr. Rita Baxmann
Marketing Communications Manager
Phone: +49 3302 883 303
Phone: 978-387-5712
E-mail: rita.baxmann@thermofisher.com
Email: amy.crosby@thermofisher.com
SOURCE Thermo Fisher Scientific
